WP
IMVT icon

Woodline Partners’s Immunovant IMVT Stock Holding History

Woodline Partners’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.1M Hold
1,975,869
– – 0.19% 140
2025
Q4 		$50.2M Buy
1,975,869
+477,144
+32% +$10.6M 0.19% 127
2025
Q3 		$24.2M Hold
1,498,725
– – 0.11% 241
2025
Q2 		$24M Buy
1,498,725
+856
+0.1% +$12.9K 0.13% 241
2025
Q1 		$25.6M Buy
1,497,869
+855,143
+133% +$17.9M 0.17% 179
2024
Q4 		$15.9M Sell
642,726
-772,251
-55% -$21.9M 0.11% 250
2024
Q3 		$40.3M Sell
1,414,977
-408,438
-22% -$12M 0.34% 90
2024
Q2 		$48.1M Buy
1,823,415
+533,911
+41% +$15.2M 0.46% 56
2024
Q1 		$41.7M Buy
1,289,504
+539,238
+72% +$19.7M 0.38% 73
2023
Q4 		$31.6M Sell
750,266
-213,817
-22% -$7.87M 0.34% 87
2023
Q3 		$37M Buy
964,083
+328,992
+52% +$7.44M 0.43% 54
2023
Q2 		$12M Buy
635,091
+497,499
+362% +$9.28M 0.14% 184
2023
Q1 		$2.13M Sell
137,592
-679,367
-83% -$11.8M 0.03% 408
2022
Q4 		$14.5M Sell
816,959
-947,331
-54% -$11.9M 0.19% 154
2022
Q3 		$9.85M Buy
1,764,290
+1,672,190
+1,816% +$8.17M 0.14% 199
2022
Q2 		$359K Buy
+92,100
New +$398K 0.01% 589
2021
Q4 		– Sell
-241,599
Closed -$2.1M – 743
2021
Q3 		$2.1M Sell
241,599
-3,508,976
-94% -$31.7M 0.03% 409
2021
Q2 		$39.6M Buy
3,750,575
+2,853,958
+318% +$39.8M 0.74% 30
2021
Q1 		$14.4M Buy
896,617
+594,714
+197% +$15.7M 0.32% 86
2020
Q4 		$13.9M Buy
301,903
+160,733
+114% +$7.43M 0.37% 84
2020
Q3 		$4.97M Sell
141,170
-89,738
-39% -$2.7M 0.16% 129
2020
Q2 		$5.62M Sell
230,908
-94,275
-29% -$2.02M 0.22% 104
2020
Q1 		$5.06M Buy
325,183
+52,644
+19% +$792K 0.36% 84
2019
Q4 		$4.32M Buy
+272,539
New +$3.05M 0.18% 93

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Woodline Partners's IMVT Position: Q1 2026 in Review

Woodline Partners held its Immunovant (IMVT) position steady in Q1 2026 at 1,975,869 shares worth $49.1M. The position accounts for 0.19% of the portfolio, ranked #140.

Woodline Partners first reported a position in IMVT in Q4 2019 and has held it in 24 quarters since. The position peaked at $50.2M in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Woodline Partners held 1,975,869 shares of Immunovant worth $49.1M as of Q1 2026.
  • Woodline Partners left its Immunovant share count unchanged in Q1 2026.
  • Immunovant made up 0.19% of Woodline Partners's portfolio in Q1 2026, its #140 holding.
  • Woodline Partners first reported a position in Immunovant in Q4 2019 and has held it in 24 quarters since.
  • Woodline Partners's Immunovant position peaked at $50.2M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.